brensocatib
Jump to navigation
Jump to search
Indications
- bronchiectasis* (FDA-approved for patients age >= 12 years)
* not associated with cystic fibrosis
Dosage
- 10 mg or 25 mg QD
Mechanism of action
- inhibits DPP-1 (cathepsin C)
- reduces activity of neutrophil proteases that contribute to airway inflammation[1]
More general terms
References
- ↑ 1.0 1.1 Chalmers JD et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 2025 Apr 24; 392:1569 PMID: https://pubmed.ncbi.nlm.nih.gov/40267423 https://www.nejm.org/doi/10.1056/NEJMoa2411664
Bell SC, Grimwood K. Brensocatib in bronchiectasis - A new sheriff in town? N Engl J Med 2025 Apr 24; 392:1647. PMID: https://pubmed.ncbi.nlm.nih.gov/40267431 https://www.nejm.org/doi/10.1056/NEJMe2502618